Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

In the last 5 years, FDA has actively characterized innovative ECG analysis methods for proarrhythmia assessments in clinical trials. ECG is a cornerstone of cardiac safety monitoring in toxicology and safety pharmacology with similarities between clinical and non-clinical evaluations.

A presentation was given by CitoxLab North America during SOT Annual Meeting & ToxExpo 2019, in Baltimore:

Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

 

Other posts you may like

Safety Pharmacology Annual Meeting

Join us during SPS annual meeting in Barcelona, Spain for our sponsored presentation with Amgen.

Academy of Surgical Research Meeting

September 25-27, 2019 Clearwater, FL - USA

French Association for the Laboratory Animal Science and Techniques

October 02-04, 2019 La Rochelle – FRANCE Booth #98

ERS International
Congress

September 28- October 02, 2019 Madrid, SPAIN Booth # V13